ArticleNature medicine2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 688 papers.
0numbers the graph read from it
0cells of the map it votes in
688citing papers in PubMed
79.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
688 citing papers in PubMed, 988 citations in OpenAlex.
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Key regulatory elements of the TGFβ-LRRC15 axis predict disease progression and immunotherapy resistance across cancer types.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- ASO Author Reflections: Cytoplasmic Morphology as a Window into Immune Biology in Clear Cell Renal Cell Carcinoma.Annals of surgical oncology · 2026Article
- Biomarkers in Clear Cell Renal Cell Carcinoma: From Biological Association to Clinical Decision-Making.Genes · 2026Review
- Machine learning and multi-omics clustering to map cellular rewiring and immune evasion in ccRCC.Human genomics · 2026Article
- Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction.Cancer gene therapy · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Deep visual multi-omics profiling links morphology and molecular programs in clear cell renal cell carcinoma.EMBO molecular medicine · 2026Article
- Integrated pan-cancer analysis reveals a cancer-associated fibroblast oxidative stress response signature predicting immunotherapy response and prognosis.Apoptosis : an international journal on programmed cell death · 2026Article
- SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.Nature communications · 2026Article
- Multi-omics integration and machine learning define an iron-sulfur cluster/zinc-binding protein prognostic signature in esophageal squamous cell carcinoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Integrative multi-omics analysis identifies SMIM24 as a favorable prognostic biomarker in clear cell renal cell carcinoma.Functional & integrative genomics · 2026Article
- Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes.Cell reports · 2026Article
- APOEScience advances · 2026Article
- Loss-of-Function Mutations in SWI/SNF Complexes Associated With Active Tumour Immune Microenvironment Clinical Response to Immune Checkpoint Blockade.Journal of cellular and molecular medicine · 2026Article
- Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifiesJournal for immunotherapy of cancer · 2026Article
- IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model.iScience · 2026Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
628 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 1 country.
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4543-5553
Yue HouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ziad BakounyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1906-5704
Miriam FicialHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2005-9267
Miriam Sant' AngeloHarvard Medical School, Boston, MA, USA.
Juliet FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Petra Ross-MacdonaldBristol-Myers Squibb, Princeton, NJ, USA.
Ashton C BergerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Opeyemi A JegedeDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Liudmilla ElaginaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
John SteinharterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maxine SunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Megan Wind-RotoloBristol-Myers Squibb, Princeton, NJ, USA.
Jean-Christophe PignonHarvard Medical School, Boston, MA, USA.
Andrew D CherniackDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lee LichtensteinBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Donna NeubergDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2566-3145
Paul CatalanoHarvard Medical School, Boston, MA, USA.
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7210-5616
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9736-2109
David F McDermottHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2675-5095
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0201-4444
Sabina Signoretti *Harvard Medical School, Boston, MA, USA.
Catherine J Wu *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. cwu@partners.org.ORCID http://orcid.org/0000-0002-3348-5054
Sachet A Shukla *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. sachet_shukla@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-2445-3584
Toni K Choueiri *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-9201-3217
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USBrigham and Women's Hospital · USBristol-Myers Squibb (United States) · USBeth Israel Deaconess Medical Center · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MImmunogenomic analytical approaches for research and clinical applicationsR50CA211482 · NCI · DANA-FARBER CANCER INST · PI SHUKLA, SACHET ASHOK · 2016 to 2020
$1.3MNCI NIH HHS P50 CA101942NCI NIH HHS R01 CA155010NCI NIH HHS R50 CA211482NCI NIH HHS T32 CA009172NCI NIH HHS U24 CA224331
Abstract
PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the immunogenomic determinants of the therapeutic response. Although conventional genomic markers (such as tumor mutation burden and neoantigen load) and the degree of CD8
Indexed as
AdultAgedAged, 80 and overAntigen PresentationAntineoplastic Agents, ImmunologicalCarcinoma, Renal CellCD8-Positive T-LymphocytesChromosome DeletionChromosomes, Human, Pair 6Chromosomes, Human, Pair 9Class I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsExome SequencingFemaleFluorescent Antibody TechniqueGene DeletionAntineoplastic Agents, ImmunologicalBAP1 protein, humanClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsHistocompatibility Antigens Class IIHistone DemethylasesHistone-Lysine N-MethyltransferaseKDM5C protein, humanMTOR protein, humanNivolumabPBRM1 protein, humanPIK3CA protein, humanProteasome Endopeptidase ComplexPTEN PhosphohydrolasePTEN protein, humanSETD2 protein, humanTOR Serine-Threonine KinasesTranscription FactorsTSC1 protein, humanTuberous Sclerosis Complex 1 ProteinTumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.